{"id":"https://openalex.org/W4415549323","doi":"https://doi.org/10.1681/asn.2025q0775ptv","title":"Rituximab in Atezolizumab-Associated IgA Vasculitis: A Bridge Between Renal Protection and Cancer Treatment","display_name":"Rituximab in Atezolizumab-Associated IgA Vasculitis: A Bridge Between Renal Protection and Cancer Treatment","publication_year":2025,"publication_date":"2025-10-01","ids":{"openalex":"https://openalex.org/W4415549323","doi":"https://doi.org/10.1681/asn.2025q0775ptv"},"language":"en","primary_location":{"id":"doi:10.1681/asn.2025q0775ptv","doi":"https://doi.org/10.1681/asn.2025q0775ptv","is_oa":false,"landing_page_url":"https://doi.org/10.1681/asn.2025q0775ptv","pdf_url":null,"source":{"id":"https://openalex.org/S115693375","display_name":"Journal of the American Society of Nephrology","issn_l":"1046-6673","issn":["1046-6673","1533-3450"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315620","host_organization_name":"American Society of Nephrology","host_organization_lineage":["https://openalex.org/P4310315620"],"host_organization_lineage_names":["American Society of Nephrology"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the American Society of Nephrology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5044324752","display_name":"Jose Arriola\u2010Montenegro","orcid":"https://orcid.org/0000-0001-6921-7230","observed_orcids":["https://orcid.org/0000-0001-6921-7230"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jose J Arriola Montenegro","raw_affiliation_strings":["Mayo Clinic Division of Nephrology and Hypertension, Rochester, Minnesota, United States;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic Division of Nephrology and Hypertension, Rochester, Minnesota, United States;","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111209275","display_name":"Cristina Riaza Ortiz","orcid":"https://orcid.org/0009-0004-5154-7898","observed_orcids":["https://orcid.org/0009-0004-5154-7898"]},"institutions":[{"id":"https://openalex.org/I2961216182","display_name":"Hospital Cl\u00ednico San Carlos","ror":"https://ror.org/04d0ybj29","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I2961216182","https://openalex.org/I4210139293"]},{"id":"https://openalex.org/I4210139293","display_name":"Comunidad de Madrid","ror":"https://ror.org/040scgh75","country_code":"ES","type":"government","lineage":["https://openalex.org/I4210139293"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Cristina Riaza Ortiz","raw_affiliation_strings":["Hospital Clinico San Carlos, Madrid, Community of Madrid, Spain;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospital Clinico San Carlos, Madrid, Community of Madrid, Spain;","institution_ids":["https://openalex.org/I2961216182","https://openalex.org/I4210139293"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070946918","display_name":"Sanjeev M. Sethi","orcid":"https://orcid.org/0000-0002-4536-7709","observed_orcids":["https://orcid.org/0000-0002-4536-7709"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sanjeev Sethi","raw_affiliation_strings":["Mayo Clinic Division of Experimental Pathology and Laboratory Medicine, Rochester, Minnesota, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic Division of Experimental Pathology and Laboratory Medicine, Rochester, Minnesota, United States","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5102874726","display_name":"Sandra M. Herrmann","orcid":"https://orcid.org/0000-0002-3700-4537","observed_orcids":["https://orcid.org/0000-0002-3700-4537"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sandra Herrmann","raw_affiliation_strings":["Mayo Clinic Division of Nephrology and Hypertension, Rochester, Minnesota, United States;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic Division of Nephrology and Hypertension, Rochester, Minnesota, United States;","institution_ids":["https://openalex.org/I1330342723"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.3685,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.51965674,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":91,"max":95},"biblio":{"volume":"36","issue":"10S","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.8544999957084656,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.8544999957084656,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11029","display_name":"Renal Diseases and Glomerulopathies","score":0.11469999700784683,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10697","display_name":"Vasculitis and related conditions","score":0.008500000461935997,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rituximab","display_name":"rituximab","score":0.8889999985694885},{"id":"https://openalex.org/keywords/henoch-schonlein-purpura","display_name":"IgA vasculitis","score":0.9070000052452087},{"id":"https://openalex.org/keywords/atezolizumab","display_name":"atezolizumab","score":0.9929999709129333},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.9229999780654907},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.828000009059906},{"id":"https://openalex.org/keywords/iga-nephropathy","display_name":"IgA nephropathy","score":0.8740000128746033},{"id":"https://openalex.org/keywords/crescentic-glomerulonephritis","display_name":"crescentic glomerulonephritis","score":0.9980000257492065},{"id":"https://openalex.org/keywords/acute-kidney-injury","display_name":"acute kidney injury","score":0.847000002861023},{"id":"https://openalex.org/keywords/small-cell-neuroendocrine-carcinoma","display_name":"small cell neuroendocrine carcinoma","score":0.9480000138282776},{"id":"https://openalex.org/keywords/prednisone-taper","display_name":"prednisone taper","score":0.6600000262260437},{"id":"https://openalex.org/keywords/acute-tubular-injury","display_name":"acute tubular injury","score":0.6129999756813049}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8659999966621399},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.8479999899864197},{"id":"https://openalex.org/C3019816032","wikidata":"https://www.wikidata.org/wiki/Q2575340","display_name":"Cancer treatment","level":3,"score":0.6098999977111816},{"id":"https://openalex.org/C100776233","wikidata":"https://www.wikidata.org/wiki/Q2532492","display_name":"Bridge (graph theory)","level":2,"score":0.5249999761581421},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5135999917984009},{"id":"https://openalex.org/C2781068499","wikidata":"https://www.wikidata.org/wiki/Q3242950","display_name":"Kidney cancer","level":3,"score":0.475600004196167},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4632999897003174},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.4115999937057495},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.35659998655319214},{"id":"https://openalex.org/C3019396726","wikidata":"https://www.wikidata.org/wiki/Q25104748","display_name":"Conservative treatment","level":2,"score":0.35190001130104065},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.349700003862381},{"id":"https://openalex.org/C2908856526","wikidata":"https://www.wikidata.org/wiki/Q16252627","display_name":"Antibody therapy","level":4,"score":0.33739998936653137},{"id":"https://openalex.org/C2778653478","wikidata":"https://www.wikidata.org/wiki/Q1054718","display_name":"Kidney disease","level":2,"score":0.33629998564720154},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.30230000615119934},{"id":"https://openalex.org/C2780091579","wikidata":"https://www.wikidata.org/wiki/Q9377","display_name":"Kidney","level":2,"score":0.2858999967575073},{"id":"https://openalex.org/C163864487","wikidata":"https://www.wikidata.org/wiki/Q6901461","display_name":"Monoclonal","level":4,"score":0.275299996137619},{"id":"https://openalex.org/C54847362","wikidata":"https://www.wikidata.org/wiki/Q177635","display_name":"Nephrology","level":2,"score":0.2660999894142151},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.2526000142097473},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.2522999942302704}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1681/asn.2025q0775ptv","doi":"https://doi.org/10.1681/asn.2025q0775ptv","is_oa":false,"landing_page_url":"https://doi.org/10.1681/asn.2025q0775ptv","pdf_url":null,"source":{"id":"https://openalex.org/S115693375","display_name":"Journal of the American Society of Nephrology","issn_l":"1046-6673","issn":["1046-6673","1533-3450"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315620","host_organization_name":"American Society of Nephrology","host_organization_lineage":["https://openalex.org/P4310315620"],"host_organization_lineage_names":["American Society of Nephrology"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of the American Society of Nephrology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Case Report","id":"https://openalex.org/study-designs/case-report"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7171290603","https://openalex.org/W4318053893","https://openalex.org/W4397041658","https://openalex.org/W4397046400","https://openalex.org/W4385066249","https://openalex.org/W4397046561","https://openalex.org/W4403830564","https://openalex.org/W3014869950","https://openalex.org/W4415475294","https://openalex.org/W4313410037"],"abstract_inverted_index":{"Introduction:":[0],"Immune":[1],"checkpoint":[2],"inhibitors":[3],"(ICIs)":[4],"have":[5],"significantly":[6],"improved":[7],"cancer":[8],"outcomes":[9],"but":[10,124],"can":[11],"lead":[12],"to":[13,75,144,165,194,206,221,228],"immune-related":[14],"adverse":[15],"events,":[16],"including":[17],"AKI":[18],"in":[19],"3\u20135%":[20],"of":[21,48,97,188,231],"patients.":[22],"While":[23],"acute":[24,182],"tubulointerstitial":[25],"nephritis":[26],"is":[27,242],"the":[28,125],"most":[29],"common":[30],"form,":[31],"glomerular":[32,232],"diseases":[33],"such":[34],"as":[35],"IgA":[36,50,115,172,189,237],"nephropathy":[37,173],"with":[38,54,61,82,100,128,174,181,185,216,239],"crescentic":[39,178,240],"glomerulonephritis":[40],"are":[41],"increasingly":[42],"recognized.":[43],"We":[44],"report":[45],"a":[46,106,198,217,229],"case":[47],"ICI-associated":[49],"vasculitis":[51,238],"successfully":[52],"managed":[53],"rituximab.":[55],"Case":[56],"Description:":[57],"A":[58],"75-year-old":[59],"man":[60],"metastatic":[62],"small-cell":[63],"neuroendocrine":[64],"carcinoma":[65],"and":[66,85,102,134,160,177,255],"stage":[67],"3":[68],"CKD":[69],"(baseline":[70],"creatinine":[71,131,166],"1.55":[72],"mg/dL)":[73,133],"due":[74,205],"obstructive":[76],"uropathy":[77],"s/p":[78],"nephrostomy":[79],"began":[80],"treatment":[81,99],"atezolizumab,":[83],"carboplatin,":[84],"etoposide.":[86],"His":[87],"course":[88],"was":[89,120,201,212],"complicated":[90],"by":[91],"recurrent":[92],"UTIs,":[93],"requiring":[94],"temporary":[95],"discontinuation":[96],"atezolizumab.Following":[98],"cefepime":[101],"levofloxacin,":[103],"he":[104],"developed":[105],"pruritic":[107],"rash":[108,126],"on":[109,210],"his":[110],"extremities;":[111],"skin":[112],"biopsy":[113,170],"confirmed":[114],"vasculitis.":[116],"After":[117],"resolution,":[118],"atezolizumab":[119],"resumed":[121],"(cycle":[122],"7),":[123],"recurred":[127],"high":[129],"serum":[130],"(2.7":[132],"CRP":[135],"(35.5":[136],"mg/L).":[137],"High-dose":[138],"prednisone":[139,218],"(80":[140],"mg":[141],"daily)":[142],"led":[143,220],"symptom":[145],"improvement.":[146],"Pre-treatment":[147],"labs":[148],"revealed":[149],"elevated":[150],"TNF-\u03b1":[151],"(22.8":[152],"pg/mL),":[153,156,159],"sIL2R":[154],"(2843":[155],"IL-18":[157],"(1267":[158],"urine":[161],"retinol":[162],"binding":[163],"protein":[164],"ratio":[167],"(4110":[168],"mcg/g).Kidney":[169],"showed":[171],"focal":[175],"necrotizing":[176],"glomerulonephritis,":[179],"along":[180],"tubular":[183],"injury\u2014consistent":[184],"renal":[186,222,249],"involvement":[187],"vasculitis.These":[190],"changes":[191],"were":[192],"attributed":[193],"ICI":[195],"therapy,":[196],"though":[197],"paraneoplastic":[199],"mechanism":[200],"considered":[202],"less":[203],"likely":[204],"favorable":[207],"tumor":[208],"response":[209],"imaging.Atezolizumab":[211],"discontinued.":[213],"Rituximab,":[214],"combined":[215],"taper,":[219],"recovery.":[223],"Discussion:":[224],"Atezolizumab,has":[225],"been":[226],"linked":[227],"range":[230],"pathologies.":[233],"Although":[234],"rare,":[235],"ICI-induced":[236],"features":[241],"an":[243],"emerging":[244],"entity.":[245],"Rituximab":[246],"may":[247],"support":[248],"function":[250],"while":[251],"preserving":[252],"oncologic":[253],"efficacy":[254],"reducing":[256],"corticosteroid":[257],"burden.":[258]},"counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2025-10-25T00:00:00"}